Lung Cancer Trial, Recruiting NCT06684418 Sponsor: Fudan University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06684418
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with non-small cell lung cancer (a common type of lung cancer), confirmed by a tissue or cell test
  • People whose cancer is classified as stage I (an early stage, meaning the cancer is small and has not spread far)
  • People who are 18 years of age or older
  • People who have a reasonably good level of physical functioning, as measured by a standard medical scoring system (KPS score of 70 or above — confirm with trial site)
  • People who have already had surgery to remove their lung cancer, or have had a targeted radiation treatment called SBRT, as a main treatment
  • People who had a full body scan to assess their cancer before their surgery or radiation treatment (note: if the tumour was larger than 3 cm or located in a central part of the lung, a PET/CT scan and/or a more detailed assessment of the chest lymph nodes was also required)
  • People who are willing to attend follow-up appointments after their surgery or radiation treatment
  • People who have given their written agreement to take part in the trial

Who may not be able to join:

  • People whose CT scan images are of too poor a quality to be used in the study
  • People whose scans showed a type of lung finding called a "pure ground-glass nodule" (a faint, hazy spot on the scan with no solid component)
  • People with uncontrolled epilepsy, a central nervous system condition, or a history of mental health disorders that a doctor believes could affect their ability to give informed consent or follow the study requirements
  • People who are likely to be unable to attend follow-up appointments or be contacted over time

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-18017312901

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Recurrence-free survival (RFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov